Resources

This report and accompanying table provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 2 to 15 February 2026.

This Australian Respiratory Surveillance Report (ARSR) includes information about acute respiratory illnesses including COVID-19, influenza and respiratory syncytial virus.

This report and accompanying table provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 24 November to 7 December 2025.

This report and accompanying table provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 19 January to 1 February 2026.

This report and accompanying table provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 5 to 18 January 2026.

This report and accompanying table provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 8 December 2025 to 4 January 2026.

This report compiles data gathered by the Antimicrobial Use and Resistance in Australia (AURA) systems from 2022 to 2024. It is a snapshot of information from hospitals, aged care facilities and the community, and demonstrates the use of surveillance data in safeguarding public health in Australia.

This document provides an update on the Nipah Virus Infection (NiV) cases reported in India in 2026, including the public health response in India and relevance to Australia.

These situation reports provide updates on the outbreak of Nipah virus in India. They reflect the CDC's role in monitoring disease activity, assessing risks to Australia and providing evidence-informed public health advice.

This document provides an update on the Nipah Virus Infection (NiV) cases reported in West Bengal State, India, in January 2026, including the public health response in India and relevance to Australia.

This Australian Respiratory Surveillance Report (ARSR) includes information about acute respiratory illnesses including COVID-19, influenza and respiratory syncytial virus.

The Climate and Health Expert Advisory Group met on 12 December 2025. This document provides a record of the meeting.

This strategy outlines the national approach to SARS-CoV-2 wastewater surveillance, endorsed by Environmental Health Standing Committee (enHealth), the Communicable Diseases Network Australia (CDNA) and Australian Health Protection Committee (AHPC).

This Australian Respiratory Surveillance Report (ARSR) includes information about acute respiratory illnesses including COVID-19, influenza and respiratory syncytial virus.

This collection contains Australian Respiratory Surveillance Reports from 2026. We publish these surveillance reports regularly throughout the year.

This plan outlines the processes we follow and the steps involved in managing our information and making it available online.

This document outlines how we handle your personal information if you make a public interest disclosure.

Facilities that handle security sensitive biological agents (SSBAs) can use this template to help them make sure they identify and manage all risks associated with handing SSBAs. Use of the template is not mandatory.

This tool helps entities and facilities that handle security sensitive biological agents (SSBAs) to check their compliance with the SSBA Standards. Use of this tool is not mandatory.

This document contains our procedures for facilitating and dealing with public interest disclosures relating to the Australian Centre for Disease Control.

This report covers data captured in the National Registry between 22 May 2024 and 30 June 2025.

The Security Sensitive Biological Agent (SSBA) Standards outline the handling, storage, disposal and transport requirements of confirmed and suspected SSBAs under the National Health Security Regulations 2018. Entities that handle suspected or known SSBAs must comply with these standards.

Our privacy policy sets out how we comply with the Privacy Act 1988.

These guidelines support the Security Sensitive Biological Agents (SSBA) Regulatory Scheme.

This guideline informs entities and facilities under the Security Sensitive Biological Agents (SSBA) Regulatory Scheme when and how they can allow other regulatory schemes to access secure SSBA areas or sensitive information.